Immunome (IMNM) Debt to Equity (2020 - 2021)
Immunome (IMNM) reported Debt to Equity of $0.01 for Q1 2021, up 9.14% quarter-over-quarter from $0.01 in Q4 2020.
Immunome (IMNM) Debt to Equity (2020 - 2021) Analysis & Trends
Immunome has reported Debt to Equity for 2 years, with the latest figure at $0.01 in Q1 2021.
- For the quarter ending Q1 2021, Debt to Equity changed N/A year-over-year to $0.01; the trailing twelve-month figure through Mar 2021 stood at $0.01 (changed N/A YoY), and the FY2020 full-year result was $0.01, changed N/A from the prior year.
- Debt to Equity for Q1 2021 stood at $0.01, up from $0.01 in the prior quarter.
- The five-year high for Debt to Equity was $0.01 in Q1 2021, with the low at -$0.01 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Immunome | 2.12 Bn | 1.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 0.01 |
| Dec 31, 2020 | 0.01 |
| Sep 30, 2020 | -0.01 |